摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-2,2-difluoroundec-8-en-3-yn-5-ol

中文名称
——
中文别名
——
英文名称
(Z)-2,2-difluoroundec-8-en-3-yn-5-ol
英文别名
——
(Z)-2,2-difluoroundec-8-en-3-yn-5-ol化学式
CAS
——
化学式
C11H16F2O
mdl
——
分子量
202.24
InChiKey
NAGXJVRCXBXURQ-PLNGDYQASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • PREDICTIVE MARKER OF DNMT1 INHIBITOR THERAPEUTIC EFFICACY AND METHODS OF USING THE MARKER
    申请人:Bates Paula J.
    公开号:US20140329911A1
    公开(公告)日:2014-11-06
    Provided herein are methods for predicting efficacy of a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor treatment in a subject having a cancer, methods of identifying a subject having a cancer that is more likely to respond to a DNMT1 inhibitor treatment, and methods of selecting a treatment for a subject having a cancer that include determining a level of SOX9 in a sample containing cells from a subject having a cancer. Also provided are methods of treating a subject having a cancer that include selectively administering a DNMT1 inhibitor to a subject having cancer determined to have an elevated level of SOX9 in a sample containing cells from the subject compared to a reference level. Also provided are antibodies and antigen-binding antibody fragments that specifically bind to SOX9, and nucleic acid sequences that contain at least 10 nucleotides complementary to a contiguous sequence present in a SOX9 nucleic acid for use in these methods.
  • COMPOSITIONS AND METHODS FOR MODULATING DNMT1 INHIBITOR ACTIVITY
    申请人:UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    公开号:US20150238439A1
    公开(公告)日:2015-08-27
    Some aspects of the invention include attenuating DNMT1 inhibitor activity in an animal comprising administering an antioxidant. Other aspects of the invention include methods comprising administering a composition comprising a DNMT1 inhibitor and an antioxidant. In some instances in the methods, the animal is undergoing a treatment for cancer. Additional aspects of the invention include compositions comprising a DNMT1 inhibitor and an antioxidant.
  • US8703829B2
    申请人:——
    公开号:US8703829B2
    公开(公告)日:2014-04-22
  • US9383364B2
    申请人:——
    公开号:US9383364B2
    公开(公告)日:2016-07-05
  • US9737493B2
    申请人:——
    公开号:US9737493B2
    公开(公告)日:2017-08-22
查看更多